Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dalpiciclib + Anastrozole Neoadjuvant Study in HR+/HER2- Breast Cancer
NCT04836520Phase 2Completed
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Aug 2021
- Primary completion
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of dalpiciclib in breast cancer, sponsored by Tianjin Medical University Cancer Institute and Hospital. Started Aug 2021; status: completed.
02
Drugs
dalpiciclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04836520.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04836520.